MENS (Jyong Biotech) Other Long-Term Liabilities: $0.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.00
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech Other Long-Term Liabilities?

Jyong Biotech MENS -1.00% 10 Other Long-Term Liabilities is $0.69 Mil as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Jyong Biotech's other long-term liabilities for the quarter that ended in Dec. 2025 was $0.69 Mil.

Jyong Biotech's quarterly other long-term liabilities increased from Dec. 2024 ($20.06 Mil) to Jun. 2025 ($20.31 Mil) but then declined from Jun. 2025 ($20.31 Mil) to Dec. 2025 ($0.69 Mil).

Jyong Biotech's annual other long-term liabilities increased from Dec. 2023 ($19.47 Mil) to Dec. 2024 ($20.06 Mil) but then declined from Dec. 2024 ($20.06 Mil) to Dec. 2025 ($0.69 Mil).

Jyong Biotech Other Long-Term Liabilities Related Terms

Jyong Biotech Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech Other Long-Term Liabilities Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
19.86 19.04 19.47 20.06 0.69

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial 19.47 19.69 20.06 20.31 0.69
MENS
10GF Score
Jyong Biotech Ltd MENS
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.69 Mil mean?
Jyong Biotech (MENS) has a Other Long-Term Liabilities of $0.69 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Jyong Biotech and its competitors.
Is Jyong Biotech's Other Long-Term Liabilities too high?
Jyong Biotech's current Other Long-Term Liabilities is $0.69 Mil. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's Other Long-Term Liabilities compare to CNTN and SPRB?
Jyong Biotech's Other Long-Term Liabilities of $0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Jyong Biotech and its competitors. Jyong Biotech's current Other Long-Term Liabilities is $0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current Other Long-Term Liabilities of $0.69 Mil. The current Other Long-Term Liabilities is $0.69 Mil. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Jyong Biotech (MENS), the current Other Long-Term Liabilities is $0.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price